{"id":5718,"date":"2013-03-12T14:38:00","date_gmt":"2013-03-12T14:38:00","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=5718"},"modified":"2021-08-24T02:29:06","modified_gmt":"2021-08-24T02:29:06","slug":"aspirin-and-melanoma-in-post-menopausal-women","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/aspirin-and-melanoma-in-post-menopausal-women\/","title":{"rendered":"Aspirin and Melanoma in Post-Menopausal Women"},"content":{"rendered":"\r\n<h2 class=\"wp-block-heading\">Highlights the need for a clinical trial says Oncologist<\/h2>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n<p>Medical Oncologist <a href=\"\/aus\/about-us\">Dr Andrew Haydon<\/a>, who works on cancer aspects of ASPREE, said that a recent association between aspirin and a reduced risk of developing melanoma, was a call for closer investigation of aspirin\u2019s anti-tumour effect.<\/p>\r\n\r\n\r\n\r\n<p>Melanoma is the most deadly form of skin cancer and is on the rise in Australia.<\/p>\r\n\r\n\r\n\r\n<p>\u201cThe relationship between aspirin and cancer is complex and thought to involve the anti-inflammatory properties of ASA (acetylsalicylic acid), otherwise known as aspirin,\u201d Dr Haydon said.<br \/>\u201cThe association between aspirin and melanoma in past studies has been inconsistent. This observational study of almost 60,000 post-menopausal women, a quarter of whom reported using aspirin, found a 21% reduction in the risk of developing melanoma.<\/p>\r\n\r\n\r\n\r\n<p>\u201cBecause the dose and duration of aspirin use was not clear in this study, the results are not conclusive. However, it does support the need for a large randomised clinical trial such as ASPREE (ASPirin in Reducing Events in the Elderly) to provide robust evidence of aspirin\u2019s anti-tumour effect on all cancers, including melanoma in male and females.\u201d<\/p>\r\n\r\n\r\n\r\n<div class=\"wp-block-image\">\r\n<figure class=\"alignleft size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"300\" height=\"300\" class=\"wp-image-5719\" src=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/03\/Andrew-Haydon-SMICS-Clinical-Director_square_correct-dimensions-300x300-1.jpg\" alt=\"\" \/>\r\n<figcaption><em>Above: Dr Andrew Haydon works on cancer aspects of the ASPREE trial.<\/em><\/figcaption>\r\n<\/figure>\r\n<\/div>\r\n\r\n\r\n\r\n<p>ASPREE will also weigh the potential benefits versus the risks of aspirin, such as bleeding \u2013 an issue that was raised by Tang in the accompanying press release.<\/p>\r\n\r\n\r\n\r\n<p>The ASPREE trial was recently awarded funding by the <a href=\"\/aus\/about-us\/funding-and-collaborators\">National Cancer Institute<\/a> to research aspirin\u2019s possible cancer protective effect. The ACES (ASPREE Cancer Endpoints Study), an ASPREE <a href=\"\/aus\/about-the-aspree-project\/sub-studies\/\">sub-study<\/a>, will commence this year.<\/p>\r\n\r\n\r\n\r\n<p>The paper by <a href=\"https:\/\/www.sciencedaily.com\/releases\/2013\/03\/130311091531.htm\" target=\"_blank\" rel=\"noreferrer noopener\">Tang et al<\/a>, was recently published in the Cancer Journal online.<\/p>\r\n<p><em>Updated 7.04.2021<\/em><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Medical Oncologist Dr Andrew Haydon, who works on cancer aspects of ASPREE, said a reported association between aspirin and a reduced risk of developing melanoma was a call for closer investigation of aspirin\u2019s anti-tumour effect.<\/p>\n","protected":false},"author":2,"featured_media":5722,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,18,16],"tags":[28,47],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5718"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=5718"}],"version-history":[{"count":9,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5718\/revisions"}],"predecessor-version":[{"id":8561,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5718\/revisions\/8561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media\/5722"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=5718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=5718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=5718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}